Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes
Eckert & Ziegler AG (ISIN DE0005659700, TecDAX), a specialist in medical radioisotopes, has entered into a long-term cooperation agreement with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, UJF) to produce the alpha emitter Actinium-225. The agreement envisions Eckert & Ziegler to provide the UJF research center with several million euros for investments in equipment and hot cells, as well as radium-226 as a starting material for experiments and irradiations. In return, the Eckert & Ziegler group gets exclusive access to the capacities of a pilot unit being built within the next two years close to Prague and joint rights to the process steps developed for a large-scale Ac-225 commercial production. weiter
Where science turns into business
On April 25, 2022, Federal Commissioner for East Germany, Minister of State Carsten Schneider, and Governing Mayor of Berlin Franziska Giffey visited Campus Berlin-Buch to see how the “Zukunftsort” (place of the future) is developing. weiter
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH
Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, and CantonBio Deutschland GmbH, a subsidiary of Canton Biologics Co. Ltd., a leading Chinese CDMO, today announced the successful completion of CantonBio’s acquisition of Glycotope’s service business under the newly formed FyoniBio GmbH. weiter
Combination is key
New treatments for lung and colon cancer? weiter
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife. weiter
